Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights provided by Benzinga reporters.
TARS
$81.86+Infinity%1D
Analyst Views on TARS
Wall Street analysts forecast TARS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARS is 80.75 USD with a low forecast of 51.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast TARS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARS is 80.75 USD with a low forecast of 51.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 81.350
Low
51.00
Averages
80.75
High
100.00
Current: 81.350
Low
51.00
Averages
80.75
High
100.00
Barclays
Overweight
initiated
$100
2025-12-08
Reason
Barclays
Price Target
$100
2025-12-08
initiated
Overweight
Reason
Barclays initiated coverage of Tarsus Pharmaceuticals with an Overweight rating and $100 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."
Mizuho
initiated
$100
2025-11-20
Reason
Mizuho
Price Target
$100
2025-11-20
initiated
Reason
Mizuho initiated coverage of Tarsus Pharmaceuticals with an Outperform rating and $100 price target. Tarsus is a commercial stage, ophthalmology-focused company that markets Xdemvy, the only approved treatment for Demodex blepharitis, the analyst tells investors in a research note. The firm projects peak Xdemvy sales in DB of over $2B. Mizuho's physician survey supports the bullish view, it says.
Goldman Sachs
Andrea Tan
Neutral
maintain
$45 -> $51
2025-11-06
Reason
Goldman Sachs
Andrea Tan
Price Target
$45 -> $51
2025-11-06
maintain
Neutral
Reason
Goldman Sachs analyst Andrea Tan raised the firm's price target on Tarsus Pharmaceuticals to $51 from $45 and keeps a Neutral rating on the shares.
H.C. Wainwright
Neutral
maintain
$72 -> $88
2025-10-20
Reason
H.C. Wainwright
Price Target
$72 -> $88
2025-10-20
maintain
Neutral
Reason
H.C. Wainwright raised the firm's price target on Tarsus Pharmaceuticals to $88 from $72 and keeps a Neutral rating on the shares. The firm upped its sales estimates for Xdemvy ahead of the Q3 results based on its conviction in the launch trajectory.
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
